Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and postoperative dabrafenib + trametinib in papillary craniopharyngioma
2021-000087-30Phase 2Active
- Sponsor
- Skåne University Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in Papillary craniopharyngioma (pCP), sponsored by Skåne University Hospital. Primary endpoint: Tumor response on MRI. Started Apr 2021; status: active.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Papillary craniopharyngioma (pCP)
Beyond the preview
Go deeper on 2021-000087-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000087-30.